Physician profile
Kathy Cook
NPI 1316034093
$4,677.30
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,183 · 2020: $1,414 · 2021: $629 · 2022: $702 · 2023: $733 · 2024: $16.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $749.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,350.34 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $631.62 | 2019-2023 | Ilumya |
| Abbvie INC. | $463.61 | 2019-2023 | Rinvoq, Botox |
| Pfizer INC. | $364.61 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $331.35 | 2019-2020 | |
| Janssen Biotech, INC. | $235.54 | 2019-2024 | Tremfya |
| Amgen INC. | $225.89 | 2019-2023 | Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $151.41 | 2019-2023 | Arazlo, Jublia, Duobrii |
| Celgene Corporation | $133.19 | 2019 | |
| Incyte Corporation | $113.67 | 2022-2023 | Opzelura |
| Galderma Laboratories, L.P. | $109.15 | 2019-2021 | |
| Ucb, INC. | $99.07 | 2019-2023 | Cimzia |
| Lilly USA, LLC | $84.53 | 2021-2023 | Taltz, Olumiant |
| Mayne Pharma Commercial LLC | $81.01 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $54.78 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nabriva Therapeutics, Plc | $35.71 | 2021-2022 | |
| Kyowa Kirin, INC. | $33.26 | 2020-2023 | Poteligeo |
| E.R. Squibb & Sons, L.L.C. | $31.56 | 2023 | Sotyktu |
| Blueprint Medicines Corporation | $28.50 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.65 | 2023 | Spevigo |
| Dermavant Sciences, INC. | $18.09 | 2023 | Vtama |
| Sanofi-Aventis U.S. LLC | $17.61 | 2019 | |
| Arcutis Biotherapeutics, INC. | $17.58 | 2023 | |
| Promius Pharma LLC | $15.83 | 2019 | |
| Aclaris Therapeutics, INC. | $11.73 | 2019 | |
| Biofrontera INC. | $10.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathy Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.